M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb PharmaTimesPartnership to develop nextgeneration Tcell engagers for solid tumoursM&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) PharmaTimes Partnership to develop nextgeneration Tcell engagers for solid tumours M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Innovent’s CDMO gets green light to make biologics at large Chinese plantNext: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
